Until 24 October 2017, research institutes and small and medium-sized enterprises can apply for the twelfth call of the IMI 2 initiative. This is a public partnership project supported by the EU and major pharmaceutical companies. Support usually goes to areas where progress is really urgent. Currently, for example, this is research into Alzheimer's disease. Aid worth € 130 million is now available in IMI 2, but Czech entities can only apply for part of these resources.
One of the selected topics is the vaccination of the elderly. They gradually weaken their immune systems and are therefore particularly vulnerable to infectious diseases. The aim of IMI 2 participants is to study the burden of infectious diseases in people over the age of 50, to develop and simulate programs to reduce the burden of these diseases, or to study the immune response to vaccination in people over the age of 65. The ultimate goal is to design a vaccination program for the elderly comparable to the existing vaccination program for children.
You can read the whole article here.
Comments